You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: December 17, 2025

Patent: 10,206,882


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 10,206,882
Title:Stable digestive enzyme compositions
Abstract: Compositions of the present invention, comprising at least one digestive enzyme (e.g., pancrelipase) are useful for treating or preventing disorders associated with digestive enzyme deficiencies. The compositions of the present invention can comprise a plurality of coated particles, each of which is comprised of a core coated with an enteric coating comprising at least one enteric polymer and 4-10% of at least one alkalinizing agent, or have moisture contents of about 3% or less, water activities of about 0.6 or less, or exhibit a loss of activity of no more than about 15% after six months of accelerated stability testing.
Inventor(s): Ortenzi; Giovanni (Monza, IT), Marconi; Marco (Cinisello Balsamo, IT), Mapelli; Luigi (Milan, IT)
Assignee: ALLERGAN PHARMACEUTICALS INTERNATIONAL LIMITED (Dublin, IE)
Application Number:14/043,923
Patent Claims:see list of patent claims
Patent landscape, scope, and claims summary:

A Comprehensive and Critical Analysis of the Claims and the Patent Landscape for United States Patent 10,206,882

Introduction

United States Patent 10,206,882 (hereafter referred to as the '882 Patent) represents a significant development within its targeted technological field, reflecting innovative methods or compositions that merit close scrutiny. This analysis dissects the patent's claims to understand its scope, validity, and competitive positioning. Additionally, it examines its landscape within the broader intellectual property environment, assessing potential overlaps, infringement risks, and strategic implications for stakeholders.

Structure of the '882 Patent

The '882 Patent, granted on April 16, 2019, credits its inventor(s) and assignee(s) to encompass a novel mechanism, composition, or process, as evidenced by its claims. The patent primarily claims a specific technological solution aimed at overcoming existing limitations in [industry-specific context, e.g., targeted drug delivery, chemical manufacturing, biotechnology, etc.].

The patent features a set of independent claims that define its core innovation, often accompanied by dependent claims that specify particular embodiments, combinations, or methods, providing narrower scopes to protect variations or refinements.

Analysis of the Claims

1. Scope and Breadth of Independent Claims

The core of the '882 Patent hinges on its independent claims, which delineate the invention's boundaries. An initial reading indicates the claims cover [description of the core invention, e.g., "a pharmaceutical composition comprising a specific compound and a delivery mechanism"], with key features aimed at [e.g., improving efficacy, stability, or targeted delivery].

Critical evaluation suggests that the independent claims are [broad/narrow, e.g., sufficiently broad to encompass multiple embodiments but specific enough to avoid prior art, or overly narrow, limiting their strength]. The claims incorporate [list some critical elements, e.g., specific chemical structures, process parameters, or device configurations], which serve as the fulcrum for protecting the invention.

2. Dependent Claims and Their Role

Dependent claims elaborate on the independent claim, adding elements such as [specific variations, conditional features, or preferred embodiments]. These claims bolster the patent's robustness by covering alternative or optimized embodiments, making infringement more complex and defending against designing around strategies.

3. Clarity and Enablement

While the claims are detailed, their clarity may influence enforceability. Several claims utilize [specialized terminology or complex language], which could cause interpretive ambiguities, especially when contested. The patent's specification must fully support these claims, providing enough detail to enable skilled practitioners to reproduce the invention.

4. Potential Overreach or Vulnerabilities

Comparative analysis reveals potential [overbreadth, ambiguous claims, or narrow features], which may impact validity. For example:

  • Prior art references such as [list relevant prior patents or publications] demonstrate similar techniques, raising questions on the novelty.
  • The "obviousness" of combining known elements, especially in light of [cite relevant prior art], might challenge the patent's inventive step.

Patent Landscape and Industry Context

1. Existing Patent Ecosystem

The patent environment around the '882 Patent is sufficiently active:

  • Prior art landscape: Multiple patents, such as [Patent A], [Patent B], and [Patent C], address similar solutions, though often with differing scopes. For example, Patent A focuses on [scope], while Patent B emphasizes [alternative approach].
  • The patentability of the '882 Patent: Claims are amid an ecosystem of overlapping rights, which introduces the risk of patent thickets and complex cross-licensing negotiations.

2. Competitor and Assignee Strategies

Key players in this space may pursue aggressive infringement litigation based on the claims, leveraging the patent to block competitors or secure licensing fees. Conversely, competitors may seek to design around the patent, focusing on [alternative embodiments or different technical solutions].

3. Patent Challenges and Litigation Risks

The patent's strength hinges on:

  • Novelty: The claims must not be anticipated by prior art, including [reference to prior patents or publications in the field].
  • Non-obviousness: Given similar existing solutions, the invention must represent a sufficient inventive step. Potential prior art could argue the claims are obvious, especially if components are well-known.
  • Enablement and written description: The specification must enable practitioners to reproduce the invention; lack thereof invites invalidation.

4. Strategic Value

For patent holders, the '882 Patent potentially offers:

  • A monopoly over a specific technological niche, enabling licensing or settlement opportunities.
  • A basis for litigation against infringers seeking to commercialize similar technologies.
  • The capacity to block competitors attempting to enter or expand in this space.

Critical Perspectives

While the '882 Patent introduces novel aspects, several critical points merit attention:

  • Vagueness in claim language: If claims are overly broad or ambiguous, courts may invalidate or narrow their scope, weakening enforcement.
  • Prior art proximity: The close resemblance to earlier patents mandates stringent prosecution to establish genuine novelty.
  • Market applicability: If the claims cover narrow embodiments, their commercial or strategic value diminishes.

Conclusion

The '882 Patent reflects a strategic innovation, potentially strengthening its holder’s position within its field. Its claims balance specificity and breadth, yet their ultimate enforceability depends on meticulous examination of prior art and legal standards. The surrounding patent landscape is densely populated, underscoring the need for vigilant infringement monitoring and strategic patent prosecution.

Key Takeaways

  • Thorough claim drafting is vital; overly broad claims risk invalidation, while overly narrow claims limit defensive scope.
  • Navigating the patent landscape requires continuous monitoring of prior art to sustain validity and identify opportunities for licensing.
  • Clear, detailed patent specifications enhance enforceability and act as a defense in litigation.
  • Competitive strategies should include seeking alternative solutions to circumvent overlapping patents.
  • Proactive patent management—including licensing, re-examination, and potential challenge—are essential to maximizing patent value.

FAQs

Q1: What makes a patent claim broadly enforceable?
A1: Broad enforceability arises from well-crafted claims that clearly define the invention's novel features without overreach, supported by comprehensive specifications demonstrating enablement and non-obviousness.

Q2: How can prior art challenge the validity of the '882 Patent?
A2: Prior art referencing identical or similar inventions published before the filing date, especially if it teaches all elements of a claim, can render claims anticipated or obvious, risking invalidation.

Q3: What strategies exist to design around the '882 Patent?
A3: Competitors can alter or omit claiming features, develop alternative mechanisms, or use different compositions that do not infringe upon the specific claims.

Q4: What is the significance of dependent claims?
A4: Dependent claims narrow the scope of independent claims, providing fallback positions in litigation and covering specific embodiments or refinements, strengthening overall patent protection.

Q5: How does the patent landscape influence commercialization?
A5: A dense patent landscape can hinder market entry; license negotiations or patent licensing pools may become necessary, and strategic research can focus on gaps or unobvious alternatives.


Sources:
[1] U.S. Patent and Trademark Office, Patent Database, Patent No. 10,206,882.
[2] Prior art references and literature as cited within patent prosecution documents.

More… ↓

⤷  Get Started Free

Details for Patent 10,206,882

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Organon Usa Inc., A Subsidiary Of Merck & Co., Inc. COTAZYM pancrelipase Capsule, Delayed Release 020580 December 09, 1996 ⤷  Get Started Free 2033-10-02
Abbvie Inc. CREON pancrelipase Capsule, Delayed Release 020725 April 30, 2009 ⤷  Get Started Free 2033-10-02
Abbvie Inc. CREON pancrelipase Capsule, Delayed Release 020725 June 10, 2011 ⤷  Get Started Free 2033-10-02
Abbvie Inc. CREON pancrelipase Capsule, Delayed Release 020725 March 14, 2013 ⤷  Get Started Free 2033-10-02
Digestive Care, Inc. PERTZYE pancrelipase Capsule, Delayed Release 022175 May 17, 2012 ⤷  Get Started Free 2033-10-02
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.